[哮喘治疗中的生物制剂：有哪些新进展？]
[Biologics in asthma: what's new?].
出版信息
Rev Med Suisse. 2015 Jan 14;11(456-457):20, 22-4.
PMID:25799646
Abstract
Biologic therapies such as monoclonal antibodies are currently being developed in the field of asthma. The molecules mentioned in this article, for the majority still under development, are expected to treat certain severe asthma subgroups in a more optimal way in the near future.
摘要
诸如单克隆抗体之类的生物疗法目前正在哮喘领域进行研发。本文中提到的分子，大多数仍在研发中，有望在不久的将来以更优化的方式治疗某些严重哮喘亚组。
相似文献
1
[Biologics in asthma: what's new?].[哮喘治疗中的生物制剂：有哪些新进展？]
Rev Med Suisse. 2015 Jan 14;11(456-457):20, 22-4.
2
Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.儿童哮喘：基于指南的治疗、奥马珠单抗及其他潜在生物制剂
Immunol Allergy Clin North Am. 2015 Feb;35(1):129-44. doi: 10.1016/j.iac.2014.09.005. Epub 2014 Nov 21.
3
Biologics for paediatric severe asthma: trick or TREAT?用于儿童重度哮喘的生物制剂：噱头还是治疗手段？
Lancet Respir Med. 2019 Apr;7(4):294-296. doi: 10.1016/S2213-2600(19)30045-1. Epub 2019 Feb 26.
4
[Oral steroids downgraded, biologics upgraded].[口服类固醇降级，生物制剂升级]
MMW Fortschr Med. 2016 May 25;158(10):86. doi: 10.1007/s15006-016-8293-6.
5
Taking the red out of eosinophilic inflammation in COPD.消除慢性阻塞性肺疾病中嗜酸性粒细胞炎症的红色因素
J Allergy Clin Immunol. 2020 Aug;146(2):278-279. doi: 10.1016/j.jaci.2020.05.028. Epub 2020 Jun 2.
6
[CME. Biologics in vasculitis].
Praxis (Bern 1994). 2015 Jan 2;104(1):7-16; quiz 15. doi: 10.1024/1661-8157/a001876.
7
Advancing Care in Severe Asthma: The Art of Switching Biologics.推进重症哮喘护理：生物制剂转换的艺术。
Adv Respir Med. 2024 Feb 21;92(2):110-122. doi: 10.3390/arm92020014.
8
Biologics for severe asthma.用于重度哮喘的生物制剂。
Nursing. 2024 Apr 1;54(4):13-15. doi: 10.1097/01.NURSE.0001007624.74890.2b. Epub 2024 Mar 22.
9
Non-optimal methodology questions indirect treatment comparison of dupilumab vs. other biologics in severe asthma.非最佳方法学对度普利尤单抗与其他生物制剂在重度哮喘中的间接治疗比较提出了质疑。
Respir Med. 2022 Jan;191:105999. doi: 10.1016/j.rmed.2020.105999. Epub 2020 May 15.
10
Response to the correspondence: "Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma".对信件的回复：“非最佳方法学对度普利尤单抗与其他生物制剂在重度哮喘中的间接治疗比较提出质疑”
Respir Med. 2022 Jan;191:106088. doi: 10.1016/j.rmed.2020.106088. Epub 2020 Jul 9.
Zotero 插件